Bristol-Myers Squibb Co
NYSE : BMY$59.75−1.27%Oct 16 close
Financials
A full-history view is not released for this statement yet. This is the statement exactly as one filing printed it.
CONSOLIDATED STATEMENTS OF EARNINGS
USD · reported units. Click a value to inspect its source.
| Reported line item | Apr 1, 2026 to Jun 30, 2026 (current) | Jan 1, 2026 to Jun 30, 2026 | Apr 1, 2025 to Jun 30, 2025 | Jan 1, 2025 to Jun 30, 2025 |
|---|---|---|---|---|
| Income Statement [Abstract] | ||||
| Statement [Table] | ||||
| Product and Service [Axis] | ||||
| Product and Service [Domain] | ||||
| Net product sales | ||||
| Alliance and other revenues | ||||
| Statement [Line Items] | ||||
| Total Revenues | ||||
| Cost of products sold | ||||
| Selling, general and administrative | ||||
| Research and development | ||||
| Acquired IPRD | ||||
| Amortization of acquired intangible assets | ||||
| Other (income)/expense, net | ||||
| Total Expenses | ||||
| Earnings/(Loss) before income taxes | ||||
| Income tax provision | ||||
| Net earnings/(loss) | ||||
| Noncontrolling interest | ||||
| Net earnings/(loss) attributable to BMS | ||||
| Earnings/(Loss) per common share: | ||||
| Basic (usd per share)USD / share | ||||
| Diluted (usd per share)USD / share |
15 line items · 4 reported periodsOriginal filing order · parentheses indicate negative amounts
Each column reflects this filing’s presentation. Original line items and period dates are preserved.